Export 10 results:
Autore Titolo Tipo [ Anno(Asc)]
Filtri: Autore è di Iasio, Maria Grazia  [Clear All Filters]
2013
di Iasio MGrazia, Zauli G. The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells. Invest New Drugs 2013;31(2):458-60.
2012
Secchiero P, Rimondi E, di Iasio MGrazia, Voltan R, Gonelli A, Zauli G. Activation of the p53 pathway induces α-smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. J Cell Physiol 2012;227(5):1829-37.
Tisato V, Zauli G, Voltan R, Gianesini S, di Iasio MGrazia, Volpi I, Fiorentini G, Zamboni P, Secchiero P. Endothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype. PLoS One 2012;7(6):e39543.
Rimondi E, di Iasio MGrazia, Gonelli A, Celeghini C, Secchiero P, Zauli G. Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. Invest New Drugs 2012;30(4):1731-5.
di Iasio MGrazia, Addobbati R, Radillo O, Voltan R. Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs 2012;30(4):1761-5.
di Iasio MGrazia, Norcio A, Melloni E, Zauli G. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs 2012;30(6):2403-6.
Zauli G, Celeghini C, Melloni E, Voltan R, Ongari M, Tiribelli M, di Iasio MGrazia, Lanza F, Secchiero P. The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica 2012;97(11):1722-30.
2011
Zauli G, Voltan R, di Iasio MGrazia, Bosco R, Melloni E, Sana MElena, Secchiero P. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells. Clin Cancer Res 2011;17(9):2712-24.
Corallini F, Celeghini C, Rimondi E, di Iasio MGrazia, Gonelli A, Secchiero P, Zauli G. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 2011;226(9):2279-86.
2010
Zauli G, Toffoli B, di Iasio MGrazia, Celeghini C, Fabris B, Secchiero P. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes 2010;59(5):1261-5.

Amministrazione Trasparente